Literature DB >> 12842050

The crystal structure of human angiogenin in complex with an antitumor neutralizing antibody.

Gayatri B Chavali1, Anastassios C Papageorgiou, Karen A Olson, James W Fett, Guo fu Hu, Robert Shapiro, K Ravi Acharya.   

Abstract

The murine monoclonal antibody 26-2F neutralizes the angiogenic and ribonucleolytic activities of human angiogenin (ANG) and is highly effective in preventing the establishment and metastatic dissemination of human tumors in athymic mice. Here we report a 2.0 A resolution crystal structure for the complex of ANG with the Fab fragment of 26-2F that reveals the detailed interactions between ANG and the complementarity-determining regions (CDRs) of the antibody. Surprisingly, Fab binding induces a dramatic conformational change in the cell binding region of ANG at the opposite end of the molecule from the combining site; crosslinking experiments indicate that this rearrangement also occurs in solution. The ANG-Fab complex structure should be invaluable for designing maximally humanized versions of 26-2F for potential clinical use.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842050     DOI: 10.1016/s0969-2126(03)00131-x

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  11 in total

1.  Predicting interaction sites from the energetics of isolated proteins: a new approach to epitope mapping.

Authors:  Guido Scarabelli; Giulia Morra; Giorgio Colombo
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

2.  Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance.

Authors:  Shuping Li; Miaofen G Hu; Yeqing Sun; Norie Yoshioka; Soichiro Ibaragi; Jinghao Sheng; Guangjie Sun; Koji Kishimoto; Guo-Fu Hu
Journal:  Mol Cancer Res       Date:  2013-07-12       Impact factor: 5.852

3.  Angiogenin-mediated rRNA transcription in cancer and neurodegeneration.

Authors:  Shuping Li; Guo-Fu Hu
Journal:  Int J Biochem Mol Biol       Date:  2010

4.  Structural insight into distinct mechanisms of protease inhibition by antibodies.

Authors:  Yan Wu; Charles Eigenbrot; Wei-Ching Liang; Scott Stawicki; Steven Shia; Bin Fan; Rajkumar Ganesan; Michael T Lipari; Daniel Kirchhofer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-05       Impact factor: 11.205

5.  Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis.

Authors:  David Wu; Wenhao Yu; Hiroko Kishikawa; Rebecca D Folkerth; A John Iafrate; Yiping Shen; Winnie Xin; Katherine Sims; Guo-Fu Hu
Journal:  Ann Neurol       Date:  2007-12       Impact factor: 10.422

6.  Crystal structure of human prion protein bound to a therapeutic antibody.

Authors:  S V Antonyuk; C R Trevitt; R W Strange; G S Jackson; D Sangar; M Batchelor; S Cooper; C Fraser; S Jones; T Georgiou; A Khalili-Shirazi; A R Clarke; S S Hasnain; J Collinge
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-09       Impact factor: 11.205

7.  Characterization of the angiogenic activity of zebrafish ribonucleases.

Authors:  Daria M Monti; Wenhao Yu; Elio Pizzo; Kaori Shima; Miaofen G Hu; Chiara Di Malta; Renata Piccoli; Giuseppe D'Alessio; Guo-Fu Hu
Journal:  FEBS J       Date:  2009-06-22       Impact factor: 5.542

8.  Crystal structure of human angiogenin with an engineered loop exhibits conformational flexibility at the functional regions of the molecule.

Authors:  Nethaji Thiyagarajan; K Ravi Acharya
Journal:  FEBS Open Bio       Date:  2012-12-26       Impact factor: 2.693

9.  Epitope mapping and in silico characterization of interactions between Der p 7 allergen and MoAb WH9.

Authors:  Hsiao-Yun Tai; Jia-Kai Zhou; Hong Chou; Ming F Tam; Yu-Sen Chen; Sheh-Yi Sheu; Horng-Der Shen
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  An apoptosis-associated mammary protein deficiency leads to enhanced production of IgM antibodies against multiple damage-associated molecules.

Authors:  Miho Chikazawa; Natsuki Otaki; Takahiro Shibata; Takehiko Yasueda; Tsukasa Matsuda; Koji Uchida
Journal:  PLoS One       Date:  2013-07-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.